The plaintiffs claim that Qiagen's QIAseq kits infringe Archer's US Patent No. 10,017,810, which covers parts of its Anchored Multiplex PCR (AMP) technology.
The firm has inked a number of significant deals over the past year and presented research involving new assays at last week's American Molecular Pathology meeting.
An Associated Press poll finds that most US adults say they'd want to know whether they carried a gene variant predisposing them to an incurable disease.
